Armistice Capital LLC Sells 100,000 Shares of Alto Neuroscience, Inc. $ANRO

Armistice Capital LLC lowered its stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 6.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,536,000 shares of the company’s stock after selling 100,000 shares during the quarter. Armistice Capital LLC owned approximately 4.94% of Alto Neuroscience worth $27,341,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in Alto Neuroscience in the 1st quarter valued at about $52,000. Torren Management LLC acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $62,000. Invesco Ltd. acquired a new stake in Alto Neuroscience during the 1st quarter worth approximately $67,000. Bridgeway Capital Management LLC raised its holdings in Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after buying an additional 25,000 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new position in Alto Neuroscience during the 4th quarter worth approximately $221,000.

Analyst Upgrades and Downgrades

ANRO has been the subject of several research reports. JonesTrading decreased their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Robert W. Baird cut their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Bank of America initiated coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective on the stock. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $21.87 on Thursday. The stock has a market cap of $767.49 million, a P/E ratio of -9.04 and a beta of 1.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The company has a fifty day moving average price of $22.68 and a two-hundred day moving average price of $19.72. Alto Neuroscience, Inc. has a one year low of $2.15 and a one year high of $28.44.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.